News
SGP
28.22
+2.62%
0.72
Spyglass Pharma Approves 2025 Executive Performance Bonuses
Reuters · 21h ago
SpyGlass Pharma Insiders Make a Massive High-Stakes Bet on the Company’s Future
TipRanks · 2d ago
Spyglass Pharma Director Bilal Arshad Khan Reports Acquisition of Common Shares
Reuters · 2d ago
Wednesday 2/11 Insider Buying Report: SGP, ARES
NASDAQ · 3d ago
Major Insider Moves Signal Growing Confidence in SpyGlass Pharma
TipRanks · 3d ago
Opening Day: SpyGlass Pharma soars in debut after strongly priced IPO
TipRanks · 5d ago
Weekly Report: what happened at SGP last week (0202-0206)?
Weekly Report · 5d ago
U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years
Seeking Alpha · 02/07 03:00
SpyGlass Pharma surges on public debut; AgomAb falls
Seeking Alpha · 02/06 19:16
BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina
Reuters · 02/06 18:45
SpyGlass Pharma Stock Jumps in First Day of Trading
Dow Jones · 02/06 18:24
BUZZ-SpyGlass surges in Nasdaq debut after $150 million IPO
Reuters · 02/06 17:22
SpyGlass Pharma opens at $24.00, IPO priced at $16.00
TipRanks · 02/06 17:15
SpyGlass Agomab to make Nasdaq debuts with a combined $350M offering
Seeking Alpha · 02/06 17:13
SpyGlass Pharma indicated to open at $30, IPO priced at $16
TipRanks · 02/06 17:00
BUZZ-SpyGlass poised to open higher in Nasdaq debut after $150 million IPO
Reuters · 02/06 16:00
SpyGlass Pharma 9.375M share IPO priced at $16.00
TipRanks · 02/06 00:10
SPYGLASS PHARMA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
Reuters · 02/06 00:00
SPYGLASS PHARMA INC - EXPECTS $150 MLN GROSS PROCEEDS FROM IPO
Reuters · 02/06 00:00
More
Webull provides a variety of real-time SGP stock news. You can receive the latest news about SpyGlass Pharma, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SGP
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused in the development of the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The Company develops a non-bioerodible drug delivery technology, designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye. Its lead product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System) is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma or ocular hypertension.